KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amgen (AMGN) EBIT (2016 - 2025)

Amgen has reported EBIT over the past 17 years, most recently at $2.7 billion for Q4 2025.

  • Quarterly results put EBIT at $2.7 billion for Q4 2025, up 17.7% from a year ago — trailing twelve months through Dec 2025 was $9.1 billion (up 25.1% YoY), and the annual figure for FY2025 was $9.1 billion, up 25.1%.
  • EBIT for Q4 2025 was $2.7 billion at Amgen, up from $2.5 billion in the prior quarter.
  • Over the last five years, EBIT for AMGN hit a ceiling of $2.7 billion in Q4 2025 and a floor of $828.0 million in Q2 2021.
  • Median EBIT over the past 5 years was $2.2 billion (2022), compared with a mean of $2.1 billion.
  • Biggest five-year swings in EBIT: crashed 64.36% in 2021 and later soared 162.8% in 2022.
  • Amgen's EBIT stood at $2.3 billion in 2021, then dropped by 3.21% to $2.2 billion in 2022, then plummeted by 43.0% to $1.3 billion in 2023, then skyrocketed by 81.83% to $2.3 billion in 2024, then grew by 17.7% to $2.7 billion in 2025.
  • The last three reported values for EBIT were $2.7 billion (Q4 2025), $2.5 billion (Q3 2025), and $2.7 billion (Q2 2025) per Business Quant data.